Unknown

Dataset Information

0

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.


ABSTRACT: OBJECTIVE:In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. METHODS:Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5?mg/kg every 3?weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12?months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed. RESULTS:The PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population. CONCLUSIONS:Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1?cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored.

SUBMITTER: Gonzalez Martin A 

PROVIDER: S-EPMC6338677 | biostudies-other | 2019 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín Antonio A   Oza Amit M AM   Embleton Andrew C AC   Pfisterer Jacobus J   Ledermann Jonathan A JA   Pujade-Lauraine Eric E   Kristensen Gunnar G   Bertrand Monique A MA   Beale Philip P   Cervantes Andrés A   Kent Emma E   Kaplan Richard S RS   Parmar Mahesh K B MKB   Scotto Nana N   Perren Timothy J TJ  

Gynecologic oncology 20181116 1


<h4>Objective</h4>In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease.<h4>Methods</h4>Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were rand  ...[more]

Similar Datasets

| S-EPMC5665762 | biostudies-literature
| S-EPMC6179372 | biostudies-literature
| S-EPMC7127949 | biostudies-literature
| S-EPMC7306189 | biostudies-literature
| S-EPMC4201043 | biostudies-literature
| S-EPMC7078205 | biostudies-literature
| S-EPMC5181120 | biostudies-literature
| S-EPMC5081077 | biostudies-literature
| S-EPMC7073274 | biostudies-literature
| S-EPMC8488507 | biostudies-literature